title: Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone.
abstract: To assess the growth-promoting effect of different doses of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in GH deficiency (GHD) of hypothalamic origin, 43 prepubertal children aged between 4.3 and 18.9 years (mean 10.4 +/- 2.9 years) were randomly assigned to three treatment regimens: low-dose GHRH(1-29)-NH2 (LD group; n = 15), high-dose GHRH(1-29)-NH2 (HD group; n = 12) and GH (GH group; n = 16). The LD group received GHRH(1-29)-NH2 at 30 micrograms/kg/day s.c. in three daily doses, the HD group received 60 micrograms/kg/day s.c. in three daily doses and the GH group received GH, 0.1 IU/kg/day s.c. once daily. All children were treated for a period of 6 months. Evaluation included anthropometry, bone age, intravenous and subcutaneous GHRH(1-29)-NH2 tests and determination of insulin-like growth factor I (IGF-I) levels. An increase in height velocity of 2 cm/year or more was observed in all except two children. Height velocity during treatment was lowest in the LD group, but comparable in the HD and GH groups. An increase in height SDS for bone age occurred only in the GH-treated group. GH responses to intravenous GHRH(1-29)-NH2 showed a priming effect of the LD GHRH(1-29)-NH2 treatment, while a decrease in response occurred in the GH-treated group. Following a subcutaneous test dose of one-third of the daily dose of GHRH(1-29)-NH2, GH levels remained unchanged in both the LD and HD groups. There was accumulation of GHRH immunoreactivity over time in the HD group, but there was no correlation between measured GHRH and GH levels.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Paediatrics, Istanbul Faculty of Medicine, Turkey.
authors.forename: O
authors.initials: O
authors.lastname: Neyzi
authors.forename: N
authors.initials: N
authors.lastname: Yordam
authors.forename: G
authors.initials: G
authors.lastname: Ocal
authors.forename: R
authors.initials: R
authors.lastname: Bundak
authors.forename: F
authors.initials: F
authors.lastname: Darendeliler
authors.forename: E
authors.initials: E
authors.lastname: Açikgöz
authors.forename: M
authors.initials: M
authors.lastname: Berberoğlu
authors.forename: H
authors.initials: H
authors.lastname: Günöz
authors.forename: N
authors.initials: N
authors.lastname: Saka
authors.forename: A S
authors.initials: AS
authors.lastname: Calikoğlu
mesh_terms: D000293:Adolescent; D000365:Age Determination by Skeleton; D000886:Anthropometry; D001827:Body Height / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D006130:Growth Disorders / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D013006:Growth Hormone / Q000008:administration & dosage / Q000172:deficiency / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D017337:Sermorelin / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D007334:Insulin-Like Growth Factor I; D017337:Sermorelin; D013006:Growth Hormone